1.39
+0.05(+3.73%)
Currency In USD
| Previous Close | 1.34 |
| Open | 1.35 |
| Day High | 1.42 |
| Day Low | 1.33 |
| 52-Week High | 2.43 |
| 52-Week Low | 0.63 |
| Volume | 250,617 |
| Average Volume | 756,320 |
| Market Cap | 95.46M |
| PE | -0.85 |
| EPS | -1.64 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 1.09 |
| Change | 0.05 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $37.07 as of February 05, 2025 at a share price of $1.39. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $169.31 as of February 05, 2025 at a share price of $1.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 03, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer’s
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
GlobeNewswire Inc.
Jan 08, 2025 2:00 PM GMT
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on V
Vor Bio Announces $55.6 Million Private Placement
GlobeNewswire Inc.
Dec 27, 2024 2:00 PM GMT
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runwa